Background

The US Food and Drug Administration (FDA) has approved several immunotherapeutic drugs for cancer since 2010, and many more are still being evaluated in other clinical studies. These inhibitors significantly increase response rates and result in the treatment of patients with advanced cancer. However, cancer immunotherapy leads to essential cardiac toxicity properties that have become distinct from other cancer patients’ care and are mostly related to their etiology.

Aim of review

As potential implications, the occurrence of cardiovascular adverse events is particularly challenging and needs a comprehensive understanding of overall cancer-related etiology, clinical outcomes with different variable severity, and management.

Key scientific concepts of review

In terms of improving the overall survival of patients with cancer, clinicians should be careful in selecting either programmed cell death-1 (PD-1) or its programmed cell death ligand (PDL-1) inhibitors by evaluating their risk and clinical benefit for early intervention and decrease the level of morbidity and mortality of their patients. This review focuses on the effectiveness of PD-1/PL-1 antibodies and associated cardiotoxicity adverse events, including etiological mechanisms, diagnosis, and treatment.

中文翻译：

---

PD-1/PDL-1 抑制剂和心脏毒性；分子、病因和管理大纲

背景

自 2010 年以来，美国食品和药物管理局 (FDA) 已批准了几种用于癌症的免疫治疗药物，还有更多药物仍在其他临床研究中进行评估。这些抑制剂显着提高了反应率并导致晚期癌症患者的治疗。然而，癌症免疫疗法会导致基本的心脏毒性特性，这些特性已与其他癌症患者的护理不同，并且主要与其病因有关。

审查的目的

作为潜在的影响，心血管不良事件的发生尤其具有挑战性，需要全面了解癌症相关的整体病因、不同严重程度的临床结果和管理。

审查的关键科学概念

在提高癌症患者的总体生存率方面，临床医生应谨慎选择程序性细胞死亡-1（PD-1）或其程序性细胞死亡配体（PDL-1）抑制剂，评估其早期风险和临床获益。干预并降低患者的发病率和死亡率。本综述重点关注 PD-1/PL-1 抗体的有效性和相关的心脏毒性不良事件，包括病因机制、诊断和治疗。